Online inquiry

IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ996MR)

This product GTTS-WQ996MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets SLAMF7 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001282588.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57823
UniProt ID Q9NQ25
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ996MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11690MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ6821MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ13714MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RC48
GTTS-WQ404MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ2640MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 592
GTTS-WQ880MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-181
GTTS-WQ12943MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PankoMab
GTTS-WQ8144MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HH1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW